Oricell Therapeutics

Based in Shanghai, China, Oricell Therapeutics Co. , Ltd. (Shanghai), trading as Oricell Therapeutics, is a biotech company that focuses on the research and development of tumor immune cell therapy products. The company was formerly the research and development center of The Origincell Technology Group.

The company has established subsidiaries in Hong Kong and the United States. In January 2026, Oricell Therapeutics raised USD 70 million in series C1 funding co-led by new investor Shunxi Fund and returning investor Qiming Venture Partners, with participation from new investors NGS Super, E-Town International Industrial Investment, Elikon Venture and Ruifeng Capital and returning investor Qatar Investment Authority, and other investors. The company's main product pipeline includes autologous CAR-T immunotherapy products for the treatment of advanced hepatocellular carcinoma relapsed refractory multiple myeloma and other novel drugs for tumor immunotherapy. The company's products are used in diseases such as liver cancer, ovarian cancer, gastric cancer and cervical cancer.

The company generates revenue from developing cell therapies leveraging CAR-T technology. The series C1 funding will be used to accelerate the company's international expansion and clinical development process, strengthening its technological capabilities and the value of its industrial pipeline in the field of cell therapy.